PolyMedix Receives USAN Approval for Generic Name of Brilacidin for PMX-30063
Press Release: PolyMedix, Inc. – Tue, Jun 12, 2012 4:30 PM EDT
RADNOR, Pa., June 12, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. ( PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "brilacidin" (pronounced bri-la-ci-din) for PMX-30063, a first-in-class defensin mimetic antibiotic. PolyMedix recently announced positive results from a Phase 2 clinical study with brilacidin as an intravenous treatment in patients with acute bacterial skin and skin structure Staph aureus infections.
"PMX-30063, now referred to as brilacidin, is the first compound in the new cidin class of antibiotics," commented Nicholas Landekic, President and CEO of PolyMedix. "The cidins are unlike any other class of systemic antibiotic approved or in development. They imitate how our body's own immune system combats bacterial infections. Brilacidin, our lead clinical compound, kills bacteria that are resistant to other antibiotic classes, with a mechanism to which resistance is unlikely to develop. We are proud to be the pioneers in this field and look forward to advancing the clinical development of brilacidin in a Phase 2B dose optimization study."
The USAN Council has also approved the use of the nonproprietary generic name "delparantag" (pronounced del-par-an-tag) for PMX-60056, PolyMedix's first-in-class anticoagulant reversing agent.
About The USAN Council
The USAN Council serves health professionals in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships to ensure that drug information is communicated accurately and unambiguously. The USAN Council aims for global standardization and unification of drug nomenclature by working closely with the International Nonproprietary Name Programme of WHO and various national nomenclature groups. |
